Eris Lifesciences Ltd.
Snapshot View

750.10 -4.65 ▼-0.6%

05 August 2021, 04:00:00 P.M.
Volume: 11,291

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.eris.co.in
Financial Indicators
Market Cap 10,191.12 Cr.
Earnings per share (EPS) 27.44 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 27.34 Trailing Twelve Months Ending 2021-06
Industry PE 32.74 Trailing Twelve Months Ending 2021-06
Book Value / Share 124.16 Trailing Twelve Months Ending 2021-06
Price to Book Value 6.04 Calculated using Price: 750.10
Dividend Yield 0.73 Period Ending 2021-03
No. of Shares Subscribed 13.59 Cr. 135,863,494 Shares
FaceValue 1
Company Profile

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.

The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

History and milestones

  • 2007: Incorporation of the company.
  • 2007: Launched “Eris” division focused on cardiology and diabetes segment.
  • 2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
  • 2009: Launched “Adura” division focused on cardiology and diabetes segment.
  • 2011: Launched “Montana” division focused on gynecology and pediatrics segment.
  • 2012: Launched “Inspira” division focused on cardiology segment.
  • 2014: Launched “Victus” division focused on anti-diabetes segment.
  • 2014: Set up Assam Facility by the company.
  • 2015: Launched “Eris 2” division focused on pain management segment.
  • 2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
  • 2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
  • 2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
  • 2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
  • 2017: Eris acquires 40 trademarks from Amay Pharma
  • 2017: Eris acquires Pune based UTH Healthcare.
  • 2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
  • 2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
  • 2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.62%
1 Week
-2.82%
1 Month
+1.38%
3 Month
+25.42%
6 Month
+29.54%
1 Year
+38.61%
2 Year
+83.80%
5 Year
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 77.39 75.91 50.12 40.30 47.68 56.90 41.30 28.96 24.28
Return on Capital Employed (%) 107.17 103.88 68.93 49.25 54.56 62.56 35.76 26.54 25.44
Return on Assets (%) 36.38 42.75 32.09 28.59 36.17 43.89 27.31 20.02 20.33

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 48 106 177 266 300 567 861 1,151 1,296
Non Curr. Liab. 14 17 18 19 20 12 248 -66 -80
Curr. Liab. 35 44 71 65 69 129 294 377 220
Minority Int. 5 5 4 4 3 24 25 18
Equity & Liab. 102 172 270 354 392 732 1,428 1,481 1,437
Non Curr. Assets 33 45 115 191 169 463 1,061 827 902
Curr. Assets 69 126 155 163 222 270 367 653 535
Misc. Exp. not W/O
Total Assets 102 172 270 354 392 732 1,428 1,481 1,437

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 274 393 509 546 597 750 856 982 1,074
Other Income 1 1 4 3 3 25 26 32 16
Total Income 275 395 513 549 600 775 882 1,014 1,090
Total Expenditure -215 -307 -410 -424 -425 -480 -533 -637 -706
PBIDT 60 87 103 125 175 294 349 377 384
Interest -1 -1 0 0 0 -1 -11 -23 -2
Depreciation -3 -3 -5 -16 -20 -23 -26 -36 -50
Taxation -18 -25 -27 -20 -20 -24 -17 -26 -35
Exceptional Items
PAT 37 58 71 89 135 247 295 291 297

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 30 38 90 90 131 200 235 223 271
Cash Fr. Inv. -19 -36 -83 -92 -44 -184 -590 -5 123
Cash Fr. Finan. -10 -3 -2 0 -84 -24 363 -221 -335
Net Change 1 -1 5 -2 4 -8 8 -3 60
Cash & Cash Eqvt 3 2 7 5 9 2 11 8 67

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 56.23 56.23 56.23 55.55 55.55 54.08 54.23 54.13 52.69
Public 43.77 43.77 43.77 44.45 44.45 45.92 45.77 45.87 47.31
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 05 Aug 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING
Thu, 05 Aug 2021
INTIMATION OF SUBMISSION OF APPLICATION FOR RECLASSIFICATION
Pursuant to application received by the Company on February 18 2021 regarding the request for reclassification
of Promoter from Promoter category to Public category and the approvals for the same obtained
from the Board of Directors and shareholders of the Company we wish to inform you that the Company has
made an application to BSE Limited and National Stock Exchange of India Limited for re-classification of the
following persons from the Promoter and Promoter Group category to the Public category of shareholders of
the Company in accordance with Regulation 31A of the Listing Regulations.
Wed, 04 Aug 2021
NOTICE OF BOOK CLOSURE
In accordance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations 2015 we hereby inform you that the Register of Members
and Share Transfer Books of the Company will be closed on Wednesday August 25 2021 for the
purpose of Fifteenth Annual General Meeting of the Company scheduled to be held on Wednesday
September 01 2021.

Technical Scans View Details

Wed, 04 Aug 2021
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Crossing 20 EMA From Above Close Crossing 20 EMA From Above
CCI Trending Down CCI Trending Down
ROC Trending Down ROC Trending Down

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.85 +0.0%
Divi's Laboratories Ltd. 131,785.24 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,783.30 +0.2%
Cipla Ltd. 75,796.16 945.20 +0.6%
Cadila Healthcare Ltd. 60,170.47 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,075.50 +0.2%
Piramal Enterprises Ltd. 57,915.28 2,601.15 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.52 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,601.15 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.15 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,601.15 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%